
A recent study evaluated J2H-1702, a novel inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme pivotal in regulating glucose metabolism and inflammation. The study, involving 50 healthy volunteers, examined the drug's pharmacokinetics, pharmacodynamics, safety, and tolerability after a single oral dose. J2H-1702 effectively reduced 11β-HSD1 activity, displaying a dose-dependent response with peak plasma concentration observed 2–2.9 h post-administration. The drug exhibited typical elimination kinetics and was well-tolerated up to 300 mg, showing potential as a therapeutic option for nonalcoholic steatohepatitis (NASH).
Like
Save
Share